Open an account

Tectonic Therapeutic

TECX · NASDAQ

$21.83+$0.675 (+3.19%)TodayMarket closed ·
Prev close $21.15

About TECX

Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCR). The company is headquartered in Watertown, Massachusetts and currently employs 60 full-time employees. The company went IPO on 2018-06-21. The firm is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Its product candidates are TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. Its second development candidate, TX2100, is a VHH-Fc fusion antagonist antibody that binds to the APJ receptor (APLNR), also known as the apelin receptor. Its APJ is a differentiated approach for the treatment of hereditary hemorrhagic telangiectasia (HHT) and is a selective anti-angiogenic target that is primarily expressed in endothelial cells.

Employees
60
Headquarters
Watertown, Massachusetts
Listed
Jun 21, 2018
Sector
Health Care
Industry
Biotechnology
Website
tectonictx.com

TECX key statistics

Market cap
426.66M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
242.76K
Volume
144.54K
Open price
$21.22
High today
$22.44
Low today
$20.99
52 Week high
$39.53
52 Week low
$15.52

Tectonic Therapeutic (TECX) at a glance

As of Oct 20, 2026, Tectonic Therapeutic (TECX) shares are priced at $21.83, giving the company a market cap of 426.66M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $20.99 and $22.44. The current price is 4.0% above the day's low and 2.7% below its high.

Volume so far is 144.54K shares, below the average of 242.76K shares a day.

Over the past year Tectonic Therapeutic has ranged from $15.52 to $39.53, and now sits 26% of the way up that range.

Tectonic Therapeutic met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$1.18 per share against an estimate of -$1.38.

The average analyst price target is $78.16, 258.1% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

80%of 5 analyst ratings say Buy
  • Buy80.0%
  • Hold20.0%
  • Sell0.0%
Price target · 10 analystsAvg $78.16
Low
$60.60
Now
$21.83
High
$97.65

TECX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 17.0% on average.

  1. Q3 FY24: reported -$1.20 per share against an estimate of -$0.8415
  2. Q4 FY24: reported -$0.84 per share against an estimate of -$1.41
  3. Q1 FY25: reported -$0.93 per share against an estimate of -$1.11
  4. Q2 FY25: reported -$1.07 per share against an estimate of -$1.00
  5. Q3 FY25: reported -$1.02 per share against an estimate of -$1.07
  6. Q4 FY25: reported -$1.03 per share against an estimate of -$1.13
  7. Q1 FY26: reported -$1.34 per share against an estimate of -$1.21
  8. Q2 FY26: reported -$1.18 per share against an estimate of -$1.38

TECX news

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Avi Kapoor

    Canopy Growth, Nvidia And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • Avi Kapoor

    Nasdaq Moves Lower; Meta Platforms Posts Strong Sales

  • Avi Kapoor

    Dow Jumps Over 100 Points; Tesla Earnings Miss Views

  • Market-Moving News for January 30th

Similar companies

Companies in the same industry as Tectonic Therapeutic

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.